Resistance of Cancer Cells to CTL-Mediated Immunotherapy

  • Benjamin Bonavida
  • Salem Chouaib

Part of the Resistance to Targeted Anti-Cancer Therapeutics book series (RTACT, volume 7)

Table of contents

  1. Front Matter
    Pages i-xix
  2. Factors Regulating Resistance to CTL Cytotoxicity

    1. Front Matter
      Pages 1-1
    2. Veronica Catalano, Cecilia Eleuteri, Gaia Campoccia, Gianluca Giacobini, Mariangela Zane, Giorgio Stassi et al.
      Pages 3-29
    3. Wieger J. Norde, Willemijn Hobo, Harry Dolstra
      Pages 31-58
    4. Barbara Seliger, Simon Jasinski-Bergner
      Pages 59-72
    5. Marie Boutet, Stephanie Cognac, Fathia Mami-Chouaib
      Pages 73-89
    6. Janis Noonan, Brona M. Murphy
      Pages 91-112
  3. Influence of the Tumor Microenvironment on the Resistance to CTL Cytotoxicity

    1. Front Matter
      Pages 113-113
    2. Meriem Hasmim, Yosra Messai, Stéphane Terry, Bassam Janji, Muhammad Zaeem Noman, Salem Chouaib
      Pages 115-142
    3. Tuna Mutis, Niels W. C. J. van de Donk, Richard W. J. Groen
      Pages 143-158
  4. Resistance to Death Ligands-Mediated Apoptosis and Sensitization

  5. Future Directions and Challenges

    1. Front Matter
      Pages 285-285
    2. Yutaka Kawakami, Li Qian, Naoshi Kawamura, Junichiro Miyazaki, Kinya Tsubota, Tomonari Kinoshita et al.
      Pages 287-301
    3. Krishnamurthy Thyagarajan, Shilpak Chatterjee, Pravin Kesarwani, Michael I. Nishimura, Shikhar Mehrotra
      Pages 303-349
  6. Marie Boutet, Stephanie Cognac, Fathia Mami-Chouaib
    Pages E1-E1
  7. Back Matter
    Pages 351-353

About this book


This book, written by leading investigators, brings together the latest knowledge about key aspects of the most rapidly progressing fields of tumor escape and tumor resistance to CTL. Readers will benefit from a collection of outstanding surveys that cover some factors regulating resistance to CTL cytotoxicity, the influence of tumor microenvironment, and the resistance to death ligands, mediated apoptosis, and means to reverse resistance. This remarkable volume also emphasizes the future directions that may lead to the design of more innovative, refined,  and integrative immunotherapies to target tumor plasticity and heterogeneity, and help to overcome the inherent limitations of current treatments. By providing a broad scope of innovative concepts in the burgeoning field of cancer biology and immunotherapy, this volume will be of exceptional interest and a valuable reference for scientists, clinicians, health professionals, and biopharmaceutical companies working in the field of cancer immunotherapy.



HDAC inhibitors Proteasome inhibitors apoptosis cytotoxic t lymphocytes drug-resistant cancer cells epitopes

Editors and affiliations

  • Benjamin Bonavida
    • 1
  • Salem Chouaib
    • 2
  1. 1.Department of Microbiology, Immunology aUniversity of California at Los Angeles,Los AngelesUSA
  2. 2.Institut Gustave RoussyVillejuifFrance

Bibliographic information

  • DOI
  • Copyright Information Springer International Publishing Switzerland 2015
  • Publisher Name Springer, Cham
  • eBook Packages Biomedical and Life Sciences
  • Print ISBN 978-3-319-17806-6
  • Online ISBN 978-3-319-17807-3
  • Series Print ISSN 2196-5501
  • Series Online ISSN 2196-551X
  • Buy this book on publisher's site
Industry Sectors
Health & Hospitals
Oncology & Hematology
Consumer Packaged Goods